O'Neill: Pharma Is Intrigued, Irritated But Respects The UK AMR Review
This article was originally published in Scrip
Executive Summary
Lord Jim O'Neill – ex-chair of Goldman Sachs Asset Management and the man appointed by UK Prime Minister David Cameron to launch and chair a review into the crisis of antibiotic resistance – spoke to Scrip at the recent BioInfect conference about what will happen when the Review of Antimicrobial Resistance (AMR) reaches its conclusion in summer 2016, pharma's reaction to the review so far, and how China is joining the game.